What Does a HER2 FISH Negative Result Mean?

A HER2 FISH negative result means the tumor does not carry extra copies of the HER2 gene, which in turn means the cancer is unlikely to be driven by HER2 overactivity. In practical terms, this result has traditionally ruled out HER2-targeted drugs like trastuzumab. But the picture has grown more nuanced in recent years, particularly with the recognition that some FISH-negative tumors still express low levels of HER2 protein and may respond to newer antibody-drug conjugates.

What FISH Actually Measures

FISH stands for fluorescence in situ hybridization. It is a laboratory technique that uses fluorescent probes to count how many copies of the HER2 gene sit on each tumor cell’s DNA. In a typical FISH test for breast cancer, a pathologist applies two probes to a thin slice of tumor tissue: one probe binds specifically to the HER2 gene, and a second probe binds to a reference spot on chromosome 17, where HER2 naturally lives. The pathologist then counts the glowing signals under a fluorescence microscope and calculates a ratio of HER2 signals to chromosome 17 signals.

A ratio below 2.0, combined with an average HER2 gene copy number below 4.0 per cell, is classified as FISH negative under current guidelines. That combination places the tumor in what the guidelines call Group 5, the clearly non-amplified category.

When a tumor is FISH negative, the HER2 gene is present at roughly normal levels, meaning the cell is not cranking out abnormally high amounts of HER2 protein. In amplified tumors, by contrast, the gene can be present in dozens of copies, flooding the cell surface with HER2 receptors that push the cell to grow and divide aggressively. HER2 amplification or overexpression occurs in roughly 15 to 30 percent of breast cancers.

Why FISH Is Usually Ordered After an Initial Test

Most hospitals do not jump straight to FISH. The first-line test for HER2 status is immunohistochemistry, or IHC, which stains tumor tissue to see how much HER2 protein is sitting on the cell surface. IHC results are scored on a scale: 0 and 1+ are considered negative, 3+ is considered positive, and 2+ falls into an equivocal zone. FISH is typically ordered when IHC comes back 2+, because that score alone is not reliable enough to decide whether the tumor is truly HER2-driven.

A meta-analysis examining concordance between IHC and FISH found that even IHC scores of 0/1+ and 3+ cannot be completely relied on to classify tumors as negative or positive without confirmation. The researchers recommended a complementary test like FISH to validate HER2 expression.

⁴

So if your pathology report shows IHC 2+ followed by FISH negative, the combined interpretation is that the tumor is not HER2-amplified. That two-step process is the standard pathway for resolving ambiguous initial results.

What FISH Negative Means for Treatment Decisions

For years, the treatment line was simple: FISH positive meant you were eligible for HER2-targeted therapy such as trastuzumab, and FISH negative meant you were not. A FISH-negative tumor is not addicted to HER2 signaling in the way an amplified tumor is, so drugs designed to block HER2 were not expected to help.

Research supports this logic at the molecular level. Studies measuring how deeply cancer cells depend on HER2 found a strong correlation between the amount of HER2 protein a cell produces and how much the cell relies on HER2 for survival. Cells that lack HER2 overexpression show essentially no response to HER2-blocking drugs.

⁵

Instead, treatment for a FISH-negative breast cancer depends on other tumor characteristics, mainly hormone receptor status. If the tumor is hormone receptor positive, endocrine therapies and possibly CDK4/6 inhibitors become the backbone of treatment. If both HER2 and hormone receptors are negative (triple-negative breast cancer), the strategy shifts to chemotherapy, immunotherapy, or other targeted agents depending on further molecular testing.

One important nuance: data suggest that within the FISH-negative population, patients whose IHC was 2+ before FISH testing may have slightly different clinical behavior compared to those who scored IHC 0 or 1+. Among estrogen receptor-positive patients, those with IHC 2+/FISH-negative tumors had prognostic characteristics intermediate between IHC 0/1+ and HER2-positive tumors, with a higher risk of breast cancer mortality overall, though this difference did not hold within individual cancer stages.

⁶

The HER2-Low Category and Why It Matters Now

One of the most significant recent shifts in breast cancer classification involves tumors that are technically FISH negative but still express small amounts of HER2 protein. These are called HER2-low cancers, and they are far from rare. Over half of all breast cancers fall into this category, defined as IHC 1+ or IHC 2+ with a negative FISH result.

⁷

Until recently, HER2-low tumors were grouped with HER2-zero tumors and treated identically. The thinking was that if FISH was negative, the amount of HER2 present was too small to matter therapeutically. That changed with the development of antibody-drug conjugates, particularly trastuzumab deruxtecan, which delivers a potent chemotherapy payload directly to cells expressing even modest levels of HER2. Clinical trials showed meaningful responses in patients with HER2-low tumors, opening a treatment avenue that did not exist a few years ago.

This means the old binary of “HER2-positive or HER2-negative” no longer captures the full clinical reality. If your report says FISH negative, the IHC score that preceded it now carries additional weight. An IHC of 1+ or 2+ with FISH negative puts you in the HER2-low bucket, which may make you eligible for newer targeted treatments, especially in the metastatic setting. An IHC of 0 with FISH negative (or without FISH, since it would not typically be ordered) puts you in the HER2-zero category, where these newer agents have not shown the same benefit.

⁸

One study of triple-negative breast cancer patients found that those with low HER2 expression (IHC 1+ or 2+, still FISH negative) had distinct clinical features compared to those with HER2-zero tumors. Patients with IHC 2+ tumors tended to have larger tumors at diagnosis but less lymphatic and vascular invasion, fewer involved lymph nodes, a lower recurrence rate, and higher overall survival.

⁹

When a FISH Negative Result Could Be Misleading

FISH is considered a reliable test, but it is not infallible. One well-documented technical issue involves the reference probe used to calculate the HER2 ratio. The standard reference probe targets a region near the center of chromosome 17, and when that region itself is amplified (something called polysomy 17 or centromere amplification), it inflates the denominator of the ratio. This can drag the HER2/chromosome 17 ratio below 2.0 even when HER2 copy numbers are genuinely elevated. One study found this could produce falsely low ratios in as many as 22 percent of cases with apparent polysomy 17. The researchers recommended additional testing whenever a FISH-negative or equivocal result coincides with high chromosome 17 signals.

¹⁰

Tumor heterogeneity is another complication. Not every cell in a tumor is genetically identical. Some regions of a tumor may harbor HER2 amplification while others do not, and whether the pathologist’s biopsy needle landed in an amplified or non-amplified region can determine the result. Tumors with borderline FISH results, particularly those falling into what the guidelines call Group 2 (ratio at or above 2.0 but average copies below 4.0), may represent mixed populations of amplified and non-amplified cells. Some experts recommend repeat testing on an alternative tissue sample in those borderline scenarios.

¹¹

Another source of discrepancy comes from the IHC side. When IHC and molecular-level assessments of HER2 disagree, the discordance itself has been linked to worse recurrence-free survival. This is part of why clinicians take borderline or unexpected results seriously and sometimes pursue additional testing rather than treating a single result as the final word.

¹²

One institutional analysis explored what happens when FISH testing is performed on tumors that IHC had already classified as negative (not just equivocal). They found additional HER2-positive cases that IHC alone had missed, suggesting there may be value in broader FISH testing beyond the current equivocal-only protocol.

¹³

HER2 Status Can Change Over Time

A FISH negative result reflects the biology of the tissue that was sampled at that moment. When breast cancer recurs or spreads to other sites, the new tumor does not always match the original. HER2 status can shift between the primary tumor and a metastasis, going from negative to positive or vice versa. Roughly 30 percent of breast cancers may convert to or from HER2-low status upon relapse, which means the original FISH result may no longer apply.

¹⁴

A European expert panel has recommended that metastatic sites be retested for HER2 and hormone receptor status whenever feasible. Retesting is not always performed routinely, but the panel argued it is crucial for selecting the right treatment, since a patient whose original tumor was FISH negative may have a metastasis that is HER2-positive, making them newly eligible for targeted therapy they previously would not have received.

¹⁵

If you had a FISH-negative result years ago and your cancer has since recurred, asking your oncologist about retesting is reasonable. The landscape of HER2-targeted therapy has expanded, and a status change could open options that were not available or relevant at initial diagnosis.

FISH Beyond Breast Cancer

While breast cancer is where HER2 testing is most established, the same biology exists in other tumor types. HER2 overexpression occurs in an estimated 10 to 30 percent of gastric and gastroesophageal cancers, and FISH is used there as well to determine eligibility for HER2-targeted treatment.

There are key differences in how HER2 results are interpreted between breast and gastric cancer. Gastric tumors tend to show more heterogeneous HER2 staining, meaning the protein can be patchy across the tumor rather than uniformly present. The IHC scoring criteria are slightly different for gastric tissue to account for this. A FISH-negative result in gastric cancer carries the same basic meaning (no gene amplification), but the clinical framework around it reflects these tissue-specific quirks.

¹⁶

Newer Testing Technologies

Next-generation sequencing, or NGS, is increasingly used alongside or instead of traditional FISH and IHC in comprehensive tumor profiling. NGS reads the DNA of tumor cells directly and can detect HER2 gene amplification as part of a broader panel that also captures other actionable mutations. One study found complete concordance between NGS and FISH for determining HER2 amplification status across 57 patients. In one case, a tumor that was HER2-negative by IHC was found to be HER2-amplified by both NGS and FISH, received anti-HER2 therapy, and achieved a complete clinical response.

¹⁷

NGS does not replace FISH in routine clinical practice at this point, but it offers a useful cross-check, especially when IHC and FISH results are borderline or discordant. Many oncologists now order broad genomic panels that happen to include HER2 status, giving them an additional data point without requiring a separate test. For patients whose results have been ambiguous, asking whether genomic profiling might clarify HER2 status is a conversation worth having with your care team.

Tumor-Infiltrating Lymphocytes and Other Prognostic Clues in FISH-Negative Cancers

When HER2 is off the table as a treatment target, other features of the tumor become more important for predicting outcomes. One area of growing interest is tumor-infiltrating lymphocytes, or TILs, which are immune cells found within and around the tumor. In HER2-negative breast cancers, the density of these immune cells has been linked to differences in disease-free survival. A translational analysis from a large prospective trial found that among hormone receptor-negative patients, higher TIL levels were associated with significantly better disease-free survival compared to intermediate levels.

¹⁸

This finding did not hold in the hormone receptor-positive subgroup, where TIL levels did not significantly affect survival outcomes. But for triple-negative cancers, where treatment options have historically been more limited, TIL assessment adds a layer of prognostic information that helps oncologists gauge how aggressively to treat. Some institutions already report TIL levels on pathology, while others do not yet include them routinely. If your cancer is HER2 FISH negative and hormone receptor negative, asking whether TIL assessment was performed on your biopsy could provide useful context about your prognosis and immune landscape.